https://acnr.co.uk/ema-refusal-blarcamesine-anavex-alzheimers/
Blarcamesine Anavex marketing authorisation refused by EMA for Alzheimer’s disease | ACNR
Dec 12, 2025 - EMA has recommended refusing marketing authorisation for Blarcamesine Anavex for early Alzheimer’s disease.
marketing authorisationblarcamesinerefusedemadisease